Auditory changes associated with moderate blood salicylate levels.
Thirty patients with rheumatoid arthritis were randomly assigned to two groups: aspirin and placebo. Aspirin group subjects received five grain ASA capsules and placebo group subjects received lactose placebo for seven days. Blood salicylate level (BSL) and audiological evaluations were performed on Days 0, 3 and 7. BSLs never exceeded 21 mg/100 ml. BSLs during the seven days varied only slightly among aspirin group subjects but dropped consistently in the placebo group. Intra-subject comparison of scores on low versus high BSL days indicated significant differences between mean speech reception thresholds (SRT) scores and pure-tone air-conduction thresholds at all test frequencies for both groups, except at 2000 Hz for the aspirin group. Inter-group differences occurred on SRT and high-frequency pure-tone thresholds. The results indicate that moderate BSLs adversely affect hearing ability. These adverse effects appear to be temporary.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006309:Hearing / Q000187:drug effects*; D006320:Hearing Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012459:Salicylates / Q000009:adverse effects / Q000097:blood*
D010919:Placebos; D012459:Salicylates; D001241:Aspirin